872360-18-4Relevant articles and documents
A METHOD OF USING PROTEASOME INHIBITORS IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS TO TREAT CANCER
-
, (2008/12/04)
Disclosed are methods of treating cancer comprising administering to the animal, a therapeutically effective amount of proteasome inhibitors and one or more histone deacetylase inhibitor. The animal is a mammal, preferably a human or a rodent.
METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG CANCER
-
, (2008/06/13)
Disclosed are methods of treating lung cancer comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound, alone or in combination with another therapeutic.
Stereoselective enzymatic reduction of keto-salinosporamide to (-)-salinosporamide A (NPI-0052)
Manam, Rama Rao,Macherla, Venkat R.,Potts, Barbara C.M.
, p. 2537 - 2540 (2008/02/02)
Salinosporamide A (NPI-0052, 1), a highly potent 20S proteasome inhibitor, has been prepared from its ketone precursor (2) by asymmetric enzymatic reduction. The yields are quantitative with complete stereoselective conversion to the desired product, with no evidence for the undesired diastereomer. This process should lead to new synthetic strategies for the total synthesis of 1.